Home Cart 0 Sign in  

[ CAS No. 1254319-51-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1254319-51-1
Chemical Structure| 1254319-51-1
Structure of 1254319-51-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1254319-51-1 ]

Related Doc. of [ 1254319-51-1 ]

Alternatived Products of [ 1254319-51-1 ]

Product Details of [ 1254319-51-1 ]

CAS No. :1254319-51-1 MDL No. :MFCD17676936
Formula : C9H8BrNO Boiling Point : -
Linear Structure Formula :- InChI Key :DPUVAXLWVRZASN-UHFFFAOYSA-N
M.W : 226.07 Pubchem ID :46942008
Synonyms :

Calculated chemistry of [ 1254319-51-1 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.22
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 0.0
Molar Refractivity : 54.0
TPSA : 20.31 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.51 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.13
Log Po/w (XLOGP3) : 1.65
Log Po/w (WLOGP) : 1.5
Log Po/w (MLOGP) : 2.17
Log Po/w (SILICOS-IT) : 2.39
Consensus Log Po/w : 1.97

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.65
Solubility : 0.505 mg/ml ; 0.00223 mol/l
Class : Soluble
Log S (Ali) : -1.69
Solubility : 4.62 mg/ml ; 0.0204 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -3.42
Solubility : 0.0859 mg/ml ; 0.00038 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.53

Safety of [ 1254319-51-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1254319-51-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1254319-51-1 ]
  • Downstream synthetic route of [ 1254319-51-1 ]

[ 1254319-51-1 ] Synthesis Path-Upstream   1~20

  • 1
  • [ 675109-26-9 ]
  • [ 74-88-4 ]
  • [ 1254319-51-1 ]
YieldReaction ConditionsOperation in experiment
85%
Stage #1: With sodium iodide In N,N-dimethyl-formamide at 0℃; for 0.5 h; Inert atmosphere
Stage #2: at 20℃; for 1 h; Inert atmosphere
General procedure: Bromoisoindolin-1-one (2.0 g, 9.43 mmol) was dissolved with warming in DMF (150 mL),then cooled to 0°C. NaH (415 mg, 10.4 mmol) was added and the mixture stirred under N2 at 0°C for 0.5 h. Methyl iodide (0.65 mL, 10.4 mmol) was added dropwise and the reaction allowed to warm to room temperature and stir for another I h. A small quantity of water was added to quench the reaction then the DMF removed under reduced pressure to give an oily yellow residue which was dissolved in EtOAc (150 mL). This solution waswashed with water (3x100 mL), brine (100 mL) and dried (Na2SO4)., Removal of the solvent under reduced pressure gave a solid which was purified by filtration through a plug of silica gel (10percent acetone/CH2C12 as eluant). The title compound was isolated as a very pale yellow crystalline solid (1.64 g, 80percent). ‘ H NMR [400 MHz, (CD3)2S0] ö 7.85 (dd, J= 1.5, 0.6 Hz, 1 H), 7.66 (dd, J= 8.0, 1.7 Hz, 1 H), 7.59 (d, J— 8.0 Hz, I H), 4.46 (s,2 H), 3.05 (s, 3 H). LRMS (APCI) calcd for C9H8BrNO 226, 228 (MH), found 226, 228.
Reference: [1] Patent: WO2014/28968, 2014, A1, . Location in patent: Page/Page column 64; 107
[2] Journal of Medicinal Chemistry, 2013, vol. 56, # 23, p. 9542 - 9555
[3] E-Journal of Chemistry, 2011, vol. 8, # 3, p. 1108 - 1113
  • 2
  • [ 79670-17-0 ]
  • [ 74-89-5 ]
  • [ 1254319-51-1 ]
YieldReaction ConditionsOperation in experiment
100% at 50℃; for 4 h; 35.1: 6-Bromo-2-methylisoindolin-1-one
To a solution of 5-bromo-2-bromomethyl-benzoic acid methyl ester (1.00 g, 3.25 mmol) in THF (6.5 mL) was a solution of methylamine in THF (2M, 8.12 mL, 16.24 mmol).
The reaction mixture was heated at 50°C for 4 hours and then concentrated under vacuum.
The residue was taken up in EtOAc and the organic layer was then washed with an aqueous 1M HCl solution, brine, dried (Na2SO4), filtered, concentrated under vacuum to give the title compound (0.73 g, 100percent) as a yellow solid.
1H NMR (400 MHz, CDCl3): δ 3.19 (m, 3H), 4.32 (s, 2H), 7.31 (d, 1H), 7.63 (dd, 1H), 7.96 (d, 1H).
100% at 50℃; for 4 h; 35.1: 6-Bromo-2-methylisoindolin-1-one
To a solution of 5-bromo-2-bromomethyl-benzoic acid methyl ester (1.00 g, 3.25 mmol) in THF (6.5 mL) was a solution of methylamine in THF (2M, 8.12 mL, 16.24 mmol).
The reaction mixture was heated at 50° C. for 4 hours and then concentrated under vacuum.
The residue was taken up in EtOAc and the organic layer was then washed with an aqueous 1M HCl solution, brine, dried (Na2SO4), filtered, concentrated under vacuum to give the title compound (0.73 g, 100percent) as a yellow solid.
1H NMR (400 MHz, CDCl3): δ 3.19 (m, 3H), 4.32 (s, 2H), 7.31 (d, 1H), 7.63 (dd, 1H), 7.96 (d, 1H).
100% at 50℃; for 4 h; 35.1 : 6-Bromo-2-methylisoindolin-1 -oneTo a solution of 5-bromo-2-bromomethyl-benzoic acid methyl ester (1.00 g, 3.25 mmol) in THF (6.5 ml_) was a solution of methylamine in THF (2M, 8.12 ml_, 16.24 mmol). The reaction mixture was heated at 50°C for 4 hours and then concentrated under vacuum. The residue was taken up in EtOAc and the organic layer was then washed with an aqueous 1 M HCI solution, brine, dried (Na2SO4), filtered, concentrated under vacuum to give the title compound (0.73 g, 100percent) as a yellow solid.1 H NMR (400 MHz, CDCI3): 5 3.19 (m, 3H), 4.32 (s, 2H), 7.31 (d, 1 H), 7.63 (dd, 1 H), 7.96 (d, 1 H).
Reference: [1] Patent: EP2567959, 2013, A1, . Location in patent: Paragraph 0453; 0454
[2] Patent: US2013/65894, 2013, A1, . Location in patent: Paragraph 1010; 1011
[3] Patent: WO2013/37390, 2013, A1, . Location in patent: Page/Page column 201
[4] Patent: WO2015/150565, 2015, A1, . Location in patent: Page/Page column 74
[5] Patent: EP3406612, 2018, A1, . Location in patent: Paragraph 0097; 0098
  • 3
  • [ 1520080-32-3 ]
  • [ 1254319-51-1 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 4
  • [ 1304633-64-4 ]
  • [ 1254319-51-1 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 5
  • [ 1520080-31-2 ]
  • [ 1254319-51-1 ]
  • [ 1247891-93-5 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 6
  • [ 79669-50-4 ]
  • [ 74-89-5 ]
  • [ 1254319-51-1 ]
Reference: [1] Patent: WO2010/128324, 2010, A1, . Location in patent: Page/Page column 116-117
  • 7
  • [ 1248176-03-5 ]
  • [ 1254319-51-1 ]
  • [ 1247891-93-5 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 8
  • [ 1248176-03-5 ]
  • [ 1254319-51-1 ]
  • [ 1520080-47-0 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 9
  • [ 90224-73-0 ]
  • [ 1254319-51-1 ]
Reference: [1] Angewandte Chemie - International Edition, 2011, vol. 50, # 39, p. 9180 - 9184
  • 10
  • [ 699-03-6 ]
  • [ 1254319-51-1 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
[2] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
[3] Heterocycles, 2016, vol. 93, # 2, p. 705 - 713
  • 11
  • [ 1122-91-4 ]
  • [ 1254319-51-1 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
[2] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 12
  • [ 1122-91-4 ]
  • [ 1254319-51-1 ]
  • [ 1247891-93-5 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
[2] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 13
  • [ 699-03-6 ]
  • [ 1254319-51-1 ]
  • [ 1247891-93-5 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
[2] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 14
  • [ 1122-91-4 ]
  • [ 1254319-51-1 ]
  • [ 1520080-47-0 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 15
  • [ 699-03-6 ]
  • [ 1254319-51-1 ]
  • [ 1520080-47-0 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 2, p. 358 - 361
  • 16
  • [ 118-90-1 ]
  • [ 1254319-51-1 ]
Reference: [1] E-Journal of Chemistry, 2011, vol. 8, # 3, p. 1108 - 1113
  • 17
  • [ 79670-17-0 ]
  • [ 1254319-51-1 ]
Reference: [1] E-Journal of Chemistry, 2011, vol. 8, # 3, p. 1108 - 1113
  • 18
  • [ 79669-50-4 ]
  • [ 1254319-51-1 ]
Reference: [1] E-Journal of Chemistry, 2011, vol. 8, # 3, p. 1108 - 1113
  • 19
  • [ 79669-49-1 ]
  • [ 1254319-51-1 ]
Reference: [1] E-Journal of Chemistry, 2011, vol. 8, # 3, p. 1108 - 1113
  • 20
  • [ 1254319-51-1 ]
  • [ 73183-34-3 ]
  • [ 1313399-38-0 ]
YieldReaction ConditionsOperation in experiment
28% With potassium acetate In dimethyl sulfoxide at 90℃; for 5 h; Inert atmosphere 6-Bromo-2-raethylisoindolin-l-one (723 mg, 3.41 mmol), bis(pinacolato)diboron (1.04 g, 4.09 mmol), potassium acetate (1.00 g, 10.2 mmol) and PdCl2(dppf) catalyst (139 mg, 0.17 mmol) were weighed into a flask which was sealed under N2. DMSO (15 mL) was added, and the entire mixture stirred at 90°C for 5 h. Upon cooling, the reaction mixture was diluted with water (250 mL) and extracted with CH2C12 (5x50 mL). The combined CH2C12 fractions were in turn washed with water (2x100 mL), brine (100 mL), dried (Na2S04), filtered and the solvent removed under reduced pressure to yield the crude product. Purification was carried out by flash column chromatography on silica gel (20percent THF/CH2C12 as eluant) to give the title compound as a crystalline beige solid (262 mg, 28percent). NMR [400 MHz, (CD3)2SO] δ 7.91 (br s, 1 H), 7.85 (dd, J = 7.6, 1.0 Hz, 1 H), 7.59 (dd, J = 7.5, 0.6 Hz, 1 H), 4.49 (s, 2 H), 3.07 (s, 3 H), 1.32 (s, 12 H). LRMS (APCI+) calcd for Ci5H2iBN03 274 (MH+), found 274.
Reference: [1] Patent: WO2011/75784, 2011, A1, . Location in patent: Page/Page column 113-114
[2] Journal of Medicinal Chemistry, 2013, vol. 56, # 23, p. 9542 - 9555
[3] Patent: WO2017/107089, 2017, A1, . Location in patent: Page/Page column 37; 38
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1254319-51-1 ]

Bromides

Chemical Structure| 153171-22-3

[ 153171-22-3 ]

2-(4-Bromobenzyl)isoindoline-1,3-dione

Similarity: 0.98

Chemical Structure| 6941-75-9

[ 6941-75-9 ]

5-Bromoisoindoline-1,3-dione

Similarity: 0.95

Chemical Structure| 675109-26-9

[ 675109-26-9 ]

6-Bromoisoindolin-1-one

Similarity: 0.95

Chemical Structure| 435273-55-5

[ 435273-55-5 ]

4-Bromo-2-methylisoindolin-1-one

Similarity: 0.93

Chemical Structure| 5543-27-1

[ 5543-27-1 ]

(4-Bromophenyl)(pyrrolidin-1-yl)methanone

Similarity: 0.93

Amides

Chemical Structure| 153171-22-3

[ 153171-22-3 ]

2-(4-Bromobenzyl)isoindoline-1,3-dione

Similarity: 0.98

Chemical Structure| 6941-75-9

[ 6941-75-9 ]

5-Bromoisoindoline-1,3-dione

Similarity: 0.95

Chemical Structure| 675109-26-9

[ 675109-26-9 ]

6-Bromoisoindolin-1-one

Similarity: 0.95

Chemical Structure| 435273-55-5

[ 435273-55-5 ]

4-Bromo-2-methylisoindolin-1-one

Similarity: 0.93

Chemical Structure| 5543-27-1

[ 5543-27-1 ]

(4-Bromophenyl)(pyrrolidin-1-yl)methanone

Similarity: 0.93

Related Parent Nucleus of
[ 1254319-51-1 ]

Indolines

Chemical Structure| 153171-22-3

[ 153171-22-3 ]

2-(4-Bromobenzyl)isoindoline-1,3-dione

Similarity: 0.98

Chemical Structure| 6941-75-9

[ 6941-75-9 ]

5-Bromoisoindoline-1,3-dione

Similarity: 0.95

Chemical Structure| 675109-26-9

[ 675109-26-9 ]

6-Bromoisoindolin-1-one

Similarity: 0.95

Chemical Structure| 435273-55-5

[ 435273-55-5 ]

4-Bromo-2-methylisoindolin-1-one

Similarity: 0.93

Chemical Structure| 200049-46-3

[ 200049-46-3 ]

7-Bromo-2,3-dihydro-isoindol-1-one

Similarity: 0.88